PALISADE BIO, INC.

PALI

Explore Our Financial Data > Companies > PALISADE BIO, INC.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
PALI
CIK0001357459
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address7750 EL CAMINO REAL, SUITE 5200, CARLSBAD, CA, 92009
Website palisadebio.com
Phone(858) 704-4900
CEOJ. D. Finley
Employees10

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-11.84 million
Net Income$-11.84 million
Net Income to Common$-11.84 million
EPS$-2.47
View All
Balance Sheet
Cash$5.42 million
Assets$6.67 million
Liabilities$4.05 million
Common Equity$2.62 million
Liabilities & Equity$6.67 million
View All
Cash Flow Statement
Net Income$-11.84 million
Cash From Operating Activities$-9.66 million
Cash From Investing ActivitiesN/A
Cash From Financing Activities$3.73 million
Change in Cash$-5.94 million
View All
Calculations
NOPAT$-8.49 million
EBITDA$-11.83 million
Price to EarningsN/A
Price to Book$2.26
ROE-188.48%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

PALISADES ANNOUNCES RESULTS OF SHAREHOLDER MEETING AS WELL AS BOARD AND MANAGEMENT CHANGES

Palisades Goldcorp Ltd. (TSXV: PALI) ("Palisades" or the "Company") is pleased to announce that at its meeting ("Meeting") of shareholders (the "Shareholders") held yesterday Shareholders approved the re-election of Gregor Gregersen and Elizabeth Harrison to the Board of Directors of the Company (the "Board"). In addition, Collin Kettell and Philip O'Neill were elected to the Board. Former director and Chief Financial Officer Bassam Moubarak did not stand for re-election. Effective immediately,

Article Link

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan – Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics – Access the segment here Carlsbad, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutic

Article Link

Palisade reports outcomes from Phase Ib ulcerative colitis study

Outcomes from the Phase Ib cohort included a mean decrease of 62.8% in the modified Mayo score.

Article Link

BC-Most Active Stocks

Gibo Holdings Ltd. 59,408,345 0.0424

Article Link

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Colon tissue drug levels exceeded target thresholds 36 hours post-dose in completed Phase 1a MAD cohort Company advancing toward IND submission for Phase 2 study in H1 2026 Carlsbad, CA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Pali

Article Link